Brokerages expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to announce earnings of $4.05 per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Jazz Pharmaceuticals’ earnings. The highest EPS estimate is $4.17 and the lowest is $3.84. Jazz Pharmaceuticals reported earnings of $3.64 per share in the same quarter last year, which would suggest a positive year over year growth rate of 11.3%. The firm is expected to issue its next earnings results on Tuesday, February 25th.
According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year earnings of $15.86 per share for the current financial year, with EPS estimates ranging from $15.66 to $16.00. For the next fiscal year, analysts forecast that the firm will report earnings of $17.59 per share, with EPS estimates ranging from $15.57 to $19.45. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.19 by $0.91. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 27.99%. The business had revenue of $537.70 million for the quarter, compared to analysts’ expectations of $523.92 million. During the same quarter in the previous year, the business posted $3.58 earnings per share. The business’s revenue was up 14.6% compared to the same quarter last year.
A number of research analysts have weighed in on JAZZ shares. TheStreet upgraded shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Friday, November 29th. Barclays boosted their target price on shares of Jazz Pharmaceuticals from $182.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, December 2nd. BidaskClub lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating and set a $138.00 target price for the company. in a research note on Friday, September 13th. Finally, Wells Fargo & Co boosted their target price on shares of Jazz Pharmaceuticals from $168.00 to $186.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $168.71.
JAZZ stock traded up $0.63 during mid-day trading on Wednesday, reaching $149.28. 253,631 shares of the stock traded hands, compared to its average volume of 442,334. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.71 and a current ratio of 3.89. Jazz Pharmaceuticals has a one year low of $116.52 and a one year high of $154.24. The stock has a market capitalization of $8.44 billion, a PE ratio of 12.20, a PEG ratio of 0.93 and a beta of 1.15. The business has a 50-day moving average price of $147.49 and a two-hundred day moving average price of $135.28.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 10,750 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $150.00, for a total value of $1,612,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Patricia Carr sold 1,749 shares of the business’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $148.93, for a total transaction of $260,478.57. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,249 shares of company stock valued at $3,159,444. 4.30% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its holdings in Jazz Pharmaceuticals by 28.2% in the second quarter. Renaissance Technologies LLC now owns 2,555,801 shares of the specialty pharmaceutical company’s stock worth $364,355,000 after purchasing an additional 562,700 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in Jazz Pharmaceuticals by 4,979.1% in the second quarter. Nuveen Asset Management LLC now owns 1,924,270 shares of the specialty pharmaceutical company’s stock worth $274,324,000 after purchasing an additional 1,886,384 shares in the last quarter. Boston Partners raised its holdings in Jazz Pharmaceuticals by 1.8% in the third quarter. Boston Partners now owns 1,364,882 shares of the specialty pharmaceutical company’s stock worth $174,887,000 after purchasing an additional 23,859 shares in the last quarter. LSV Asset Management raised its holdings in Jazz Pharmaceuticals by 12.5% in the second quarter. LSV Asset Management now owns 1,127,120 shares of the specialty pharmaceutical company’s stock worth $160,682,000 after purchasing an additional 125,470 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in Jazz Pharmaceuticals by 46.9% in the second quarter. AQR Capital Management LLC now owns 1,057,019 shares of the specialty pharmaceutical company’s stock worth $147,496,000 after purchasing an additional 337,396 shares in the last quarter. Institutional investors and hedge funds own 89.16% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.